SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (264)9/16/2002 4:50:42 PM
From: Jibacoa  Read Replies (1) | Respond to of 7424
 
BMRN Was up 18.6% in early trading, but it closed up only 14.16%. Volume was above its daily average, after the early news today:

ZURICH, Sept 16 (Reuters) - Biotech group BioMarin Pharmaceutical Inc (NasdaqNM:BMRN - News; Zurich:BMRZn.S - News) said on Monday U.S. regulators had granted priority review to the Aldurazyme drug it is developing with Genzyme General Corp (NasdaqNM:GENZ - News).

siliconinvestor.com

The intra-day H today (5.10)almost matched the intra-day H of July 29 (5.15)Of course there is plenty of resistance above that level.<g>

siliconinvestor.com

Bernard